Asymmetry Capital Management’s Heron Therapeutics HRTX Stock Holding History

Asymmetry Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-39,273	Closed	-$727K	–	37
2019 Q3	$727K	Buy	+39,273	New	+$723K	1.56%	21
2019 Q2	–	Sell	-67,909	Closed	-$1.66M	–	34
2019 Q1	$1.66M	Buy	67,909 +37,048	+120%	+$970K	2.77%	13
2018 Q4	$801K	Sell	30,861 -24,986	-45%	-$687K	2.21%	16
2018 Q3	$1.77M	Sell	55,847 -10,641	-16%	-$396K	1.63%	28
2018 Q2	$2.58M	Sell	66,488 -10,858	-14%	-$346K	2.54%	16
2018 Q1	$2.13M	Sell	77,346 -21,835	-22%	-$495K	2.67%	13
2017 Q4	$1.79M	Buy	99,181 +36,219	+58%	+$591K	2.44%	15
2017 Q3	$1.02M	Buy	+62,962	New	+$988K	1.18%	26

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Asymmetry Capital Management's HRTX Position: Q4 2019 in Review

Asymmetry Capital Management sold out of Heron Therapeutics (HRTX) in Q4 2019, closing a stake of 39,273 shares — an estimated $727K sold.

Asymmetry Capital Management first reported a position in HRTX in Q3 2017 and held it in 8 quarters. The position peaked at $2.58M in Q2 2018. 199 funds tracked by Wall St. Rank hold HRTX as of Q4 2019.

Asymmetry Capital Management reported no remaining Heron Therapeutics position as of Q4 2019 after selling out during the quarter.
Asymmetry Capital Management sold 39,273 Heron Therapeutics shares in Q4 2019, an estimated $727K.
Asymmetry Capital Management first reported a position in Heron Therapeutics in Q3 2017 and held it in 8 quarters.
Asymmetry Capital Management's Heron Therapeutics position peaked at $2.58M in Q2 2018.
199 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2019.

Based on Asymmetry Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.